Pluristem Therapeutics Inc (PSTI)

[zzaatt]

My best guess is that stem cells as a new form of therapy will be effective as a class. Meaning that it is likely that MESO and Pluristem will have similar efficacy in similar indications, with the possibility of specific differences for some indications, based on the growth environment.

This leads to the burning question of which company will have the ability to produce cells on an "industrial scale" and provide it to the clinician in a easy to use form (off the shelf). Here's a blurb from the MESO web site:

Mesenchymal lineage cells are collected from the bone marrow of healthy adult donors and proprietary processes are utilized to expand them to a uniform, well characterized, and highly reproducible cell population. This enables manufacturing at industrial scale for commercial purposes.

I have yet to see any head to head comparison of our ability to mass produce the cells. This could be decisive if efficacy is similar. It seems like both companies are rather tight lipped about this issue, beyond asserting that they are able to do it. The paragraph above could be copied and pasted into any Pluristem presentation. So how do we differentiate?

If anybody has seen a real comparison, I'd love to have a reference to it.